In his early 20s, Pope Francis underwent surgery to remove a part of his lung affected by a severe respiratory infection.

Developing new painkilling treatments relies on the work of pain researchers to unravel the intricate neuronal circuitry and function.

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Despite its unpleasantness, pain has a critically important purpose, designed to protect the body rather than harm it.

Scientists believe this drug will be the first of a new wave of similar medications, ones that are both nonaddictive and ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say ...

It’s the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for?

There is good news for those with acute pain, as the FDA has approved a first-of-its-kind pain medication, and it’s one ...

JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Journavx can be taken with ibuprofen for its anti-inflammatory effects. The prescription medication is not in pharmacies yet, but it maybe there by the end of February. Click here to report a typo.